Global Adenovirus Vector Vaccine Market

Adenovirus Vector Vaccine Comprehensive Study by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine, Others), Application (Human, Animals), End-user (Hospitals, Ambulatory Surgical Center, Research Institutes, Others) Players and Region - Global Market Outlook to 2028

Adenovirus Vector Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Adenovirus Vector Vaccine
Adenovirus represents the class of the genetically diverse DNA viruses that can cause non-life-threatening infections related to eyes, respiratory system, gastrointestinal lining and other parts. These viruses represent promising results as a vector for delivering target antigens to various hosts due to excellent ability induce immune response. Due to these property, the new studies concluded positive results for use of adenovirus for both gene therapy and vaccine production. Adenovirus-based vectors shows various benefits when compared to other viral vectors such as wide range of tissue tropism, ease of genetic manipulation especially for large transgene DNA insertions, superior ability to induce robust transgene-specific T cell and antibody responses, easy production of the adenovirus based vaccines at large scale. Due to this, it has emerged as a preferred choice for delivering vaccine for both humans as well as animals.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Adenovirus Vector Vaccine market companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focusing on maintaining sustainable development. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Creative Biolabs (United States), Sartorius AG (Germany), Lonza (Switzerland), Merck KGaA (Germany), Cobra Biologics (United States), Thermo Fisher Scientific (United States), Boehringer Ingelheim (Germany), Oxford Biomedica (United Kingdom) and Advanced Bioscience Laboratories (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Adenovirus Vector Vaccine market by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine and Others), Application (Human and Animals) and Region.



On the basis of geography, the market of Adenovirus Vector Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-user, the sub-segment i.e. Hospitals will boost the Adenovirus Vector Vaccine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing investment in vaccine and drug development and Rising collaboration between the pharmaceutical companies and CROs for development of adenovirus vector vaccine

Market Growth Drivers:
Growing prevalence of chronic medical conditions and Rise in demand for efficient vaccines to treat infectious diseases

Challenges:
Optimizing DSP

Restraints:
Adenoviral proteins are highly immunogenic

Opportunities:
Emergence of adenovirus vectored vaccines for COVID-19 and Production of low cost adenovirus vaccines

Market Leaders and their expansionary development strategies
In January 2021, Thermo Fisher Scientific, a company offering range of instrumentation, reagents and consumables, and software and services acquired the viral-vector manufacturing business of the Novasep, a pharmaceutical company for approximately USD 875 million in cash. This acquisition is a step towards expanding Thermo Fisher capabilities in the cell and gene vaccines and therapies worldwide.
In June 2020, the Oxford Biomedica plc signed a Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre for collaborative working on scaling-up the GMP manufacture of the adenovirus vector based COVID-19 vaccine candidate, AZD1222 (previously known as ChAdOx1 nCoV-19), which has entered clinical trials at multiple sites in the UK.
In February 2021, the Janssen Biotech, a part of Johnson and Johnson submitted Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA), for its investigational single-dose coronavirus 2019 (COVID-19) vaccine candidate. The vaccine Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein

Key Target Audience
Manufacturers of Viral Vector Vaccines, Contract Research Organization and Governmental bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Adenovirus-based tuberculosis vaccine
  • Adenovirus-based HIV vaccine
  • Adenovirus-based influenza vaccine
  • Others
By Application
  • Human
  • Animals
By End-user
  • Hospitals
  • Ambulatory Surgical Center
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of chronic medical conditions
      • 3.2.2. Rise in demand for efficient vaccines to treat infectious diseases
    • 3.3. Market Challenges
      • 3.3.1. Optimizing DSP
    • 3.4. Market Trends
      • 3.4.1. Increasing investment in vaccine and drug development
      • 3.4.2. Rising collaboration between the pharmaceutical companies and CROs for development of adenovirus vector vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adenovirus Vector Vaccine, by Type, Application, End-user and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Adenovirus Vector Vaccine (Value)
      • 5.2.1. Global Adenovirus Vector Vaccine by: Type (Value)
        • 5.2.1.1. Adenovirus-based tuberculosis vaccine
        • 5.2.1.2. Adenovirus-based HIV vaccine
        • 5.2.1.3. Adenovirus-based influenza vaccine
        • 5.2.1.4. Others
      • 5.2.2. Global Adenovirus Vector Vaccine by: Application (Value)
        • 5.2.2.1. Human
        • 5.2.2.2. Animals
      • 5.2.3. Global Adenovirus Vector Vaccine by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Center
        • 5.2.3.3. Research Institutes
        • 5.2.3.4. Others
      • 5.2.4. Global Adenovirus Vector Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Adenovirus Vector Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Creative Biolabs (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sartorius AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cobra Biologics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oxford Biomedica (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Advanced Bioscience Laboratories (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Adenovirus Vector Vaccine Sale, by Type, Application, End-user and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Adenovirus Vector Vaccine (Value)
      • 7.2.1. Global Adenovirus Vector Vaccine by: Type (Value)
        • 7.2.1.1. Adenovirus-based tuberculosis vaccine
        • 7.2.1.2. Adenovirus-based HIV vaccine
        • 7.2.1.3. Adenovirus-based influenza vaccine
        • 7.2.1.4. Others
      • 7.2.2. Global Adenovirus Vector Vaccine by: Application (Value)
        • 7.2.2.1. Human
        • 7.2.2.2. Animals
      • 7.2.3. Global Adenovirus Vector Vaccine by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Center
        • 7.2.3.3. Research Institutes
        • 7.2.3.4. Others
      • 7.2.4. Global Adenovirus Vector Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adenovirus Vector Vaccine: by Type(USD Million)
  • Table 2. Adenovirus Vector Vaccine Adenovirus-based tuberculosis vaccine , by Region USD Million (2017-2022)
  • Table 3. Adenovirus Vector Vaccine Adenovirus-based HIV vaccine , by Region USD Million (2017-2022)
  • Table 4. Adenovirus Vector Vaccine Adenovirus-based influenza vaccine , by Region USD Million (2017-2022)
  • Table 5. Adenovirus Vector Vaccine Others , by Region USD Million (2017-2022)
  • Table 6. Adenovirus Vector Vaccine: by Application(USD Million)
  • Table 7. Adenovirus Vector Vaccine Human , by Region USD Million (2017-2022)
  • Table 8. Adenovirus Vector Vaccine Animals , by Region USD Million (2017-2022)
  • Table 9. Adenovirus Vector Vaccine: by End-user(USD Million)
  • Table 10. Adenovirus Vector Vaccine Hospitals , by Region USD Million (2017-2022)
  • Table 11. Adenovirus Vector Vaccine Ambulatory Surgical Center , by Region USD Million (2017-2022)
  • Table 12. Adenovirus Vector Vaccine Research Institutes , by Region USD Million (2017-2022)
  • Table 13. Adenovirus Vector Vaccine Others , by Region USD Million (2017-2022)
  • Table 14. South America Adenovirus Vector Vaccine, by Country USD Million (2017-2022)
  • Table 15. South America Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 16. South America Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 17. South America Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 18. Brazil Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 19. Brazil Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 20. Brazil Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 21. Argentina Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 22. Argentina Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 23. Argentina Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 24. Rest of South America Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 25. Rest of South America Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 26. Rest of South America Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 27. Asia Pacific Adenovirus Vector Vaccine, by Country USD Million (2017-2022)
  • Table 28. Asia Pacific Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 29. Asia Pacific Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 31. China Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 32. China Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 33. China Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 34. Japan Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 35. Japan Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 36. Japan Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 37. India Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 38. India Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 39. India Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 40. South Korea Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 41. South Korea Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 42. South Korea Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 43. Taiwan Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 44. Taiwan Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 45. Taiwan Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 46. Australia Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 47. Australia Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 48. Australia Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 52. Europe Adenovirus Vector Vaccine, by Country USD Million (2017-2022)
  • Table 53. Europe Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 54. Europe Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 55. Europe Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 56. Germany Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 57. Germany Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 58. Germany Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 59. France Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 60. France Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 61. France Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 62. Italy Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 63. Italy Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 64. Italy Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 65. United Kingdom Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 66. United Kingdom Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 67. United Kingdom Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 68. Netherlands Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 69. Netherlands Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 70. Netherlands Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 71. Rest of Europe Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 72. Rest of Europe Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 73. Rest of Europe Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 74. MEA Adenovirus Vector Vaccine, by Country USD Million (2017-2022)
  • Table 75. MEA Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 76. MEA Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 77. MEA Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 78. Middle East Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 79. Middle East Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 80. Middle East Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 81. Africa Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 82. Africa Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 83. Africa Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 84. North America Adenovirus Vector Vaccine, by Country USD Million (2017-2022)
  • Table 85. North America Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 86. North America Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 87. North America Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 88. United States Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 89. United States Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 90. United States Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 91. Canada Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 92. Canada Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 93. Canada Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 94. Mexico Adenovirus Vector Vaccine, by Type USD Million (2017-2022)
  • Table 95. Mexico Adenovirus Vector Vaccine, by Application USD Million (2017-2022)
  • Table 96. Mexico Adenovirus Vector Vaccine, by End-user USD Million (2017-2022)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Adenovirus Vector Vaccine: by Type(USD Million)
  • Table 107. Adenovirus Vector Vaccine Adenovirus-based tuberculosis vaccine , by Region USD Million (2023-2028)
  • Table 108. Adenovirus Vector Vaccine Adenovirus-based HIV vaccine , by Region USD Million (2023-2028)
  • Table 109. Adenovirus Vector Vaccine Adenovirus-based influenza vaccine , by Region USD Million (2023-2028)
  • Table 110. Adenovirus Vector Vaccine Others , by Region USD Million (2023-2028)
  • Table 111. Adenovirus Vector Vaccine: by Application(USD Million)
  • Table 112. Adenovirus Vector Vaccine Human , by Region USD Million (2023-2028)
  • Table 113. Adenovirus Vector Vaccine Animals , by Region USD Million (2023-2028)
  • Table 114. Adenovirus Vector Vaccine: by End-user(USD Million)
  • Table 115. Adenovirus Vector Vaccine Hospitals , by Region USD Million (2023-2028)
  • Table 116. Adenovirus Vector Vaccine Ambulatory Surgical Center , by Region USD Million (2023-2028)
  • Table 117. Adenovirus Vector Vaccine Research Institutes , by Region USD Million (2023-2028)
  • Table 118. Adenovirus Vector Vaccine Others , by Region USD Million (2023-2028)
  • Table 119. South America Adenovirus Vector Vaccine, by Country USD Million (2023-2028)
  • Table 120. South America Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 121. South America Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 122. South America Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 123. Brazil Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 124. Brazil Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 125. Brazil Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 126. Argentina Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 127. Argentina Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 128. Argentina Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 129. Rest of South America Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 130. Rest of South America Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 131. Rest of South America Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 132. Asia Pacific Adenovirus Vector Vaccine, by Country USD Million (2023-2028)
  • Table 133. Asia Pacific Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 134. Asia Pacific Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 135. Asia Pacific Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 136. China Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 137. China Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 138. China Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 139. Japan Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 140. Japan Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 141. Japan Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 142. India Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 143. India Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 144. India Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 145. South Korea Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 146. South Korea Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 147. South Korea Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 148. Taiwan Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 149. Taiwan Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 150. Taiwan Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 151. Australia Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 152. Australia Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 153. Australia Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 154. Rest of Asia-Pacific Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 155. Rest of Asia-Pacific Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 157. Europe Adenovirus Vector Vaccine, by Country USD Million (2023-2028)
  • Table 158. Europe Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 159. Europe Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 160. Europe Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 161. Germany Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 162. Germany Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 163. Germany Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 164. France Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 165. France Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 166. France Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 167. Italy Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 168. Italy Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 169. Italy Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 170. United Kingdom Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 171. United Kingdom Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 172. United Kingdom Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 173. Netherlands Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 174. Netherlands Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 175. Netherlands Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 176. Rest of Europe Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 177. Rest of Europe Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 178. Rest of Europe Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 179. MEA Adenovirus Vector Vaccine, by Country USD Million (2023-2028)
  • Table 180. MEA Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 181. MEA Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 182. MEA Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 183. Middle East Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 184. Middle East Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 185. Middle East Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 186. Africa Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 187. Africa Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 188. Africa Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 189. North America Adenovirus Vector Vaccine, by Country USD Million (2023-2028)
  • Table 190. North America Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 191. North America Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 192. North America Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 193. United States Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 194. United States Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 195. United States Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 196. Canada Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 197. Canada Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 198. Canada Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 199. Mexico Adenovirus Vector Vaccine, by Type USD Million (2023-2028)
  • Table 200. Mexico Adenovirus Vector Vaccine, by Application USD Million (2023-2028)
  • Table 201. Mexico Adenovirus Vector Vaccine, by End-user USD Million (2023-2028)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adenovirus Vector Vaccine: by Type USD Million (2017-2022)
  • Figure 5. Global Adenovirus Vector Vaccine: by Application USD Million (2017-2022)
  • Figure 6. Global Adenovirus Vector Vaccine: by End-user USD Million (2017-2022)
  • Figure 7. South America Adenovirus Vector Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Adenovirus Vector Vaccine Share (%), by Country
  • Figure 9. Europe Adenovirus Vector Vaccine Share (%), by Country
  • Figure 10. MEA Adenovirus Vector Vaccine Share (%), by Country
  • Figure 11. North America Adenovirus Vector Vaccine Share (%), by Country
  • Figure 12. Global Adenovirus Vector Vaccine share by Players 2022 (%)
  • Figure 13. Global Adenovirus Vector Vaccine share by Players (Top 3) 2022(%)
  • Figure 14. Global Adenovirus Vector Vaccine share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Creative Biolabs (United States) Revenue, Net Income and Gross profit
  • Figure 17. Creative Biolabs (United States) Revenue: by Geography 2022
  • Figure 18. Sartorius AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Sartorius AG (Germany) Revenue: by Geography 2022
  • Figure 20. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza (Switzerland) Revenue: by Geography 2022
  • Figure 22. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 24. Cobra Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Cobra Biologics (United States) Revenue: by Geography 2022
  • Figure 26. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 27. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 28. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 30. Oxford Biomedica (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Oxford Biomedica (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Advanced Bioscience Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Advanced Bioscience Laboratories (United States) Revenue: by Geography 2022
  • Figure 34. Global Adenovirus Vector Vaccine: by Type USD Million (2023-2028)
  • Figure 35. Global Adenovirus Vector Vaccine: by Application USD Million (2023-2028)
  • Figure 36. Global Adenovirus Vector Vaccine: by End-user USD Million (2023-2028)
  • Figure 37. South America Adenovirus Vector Vaccine Share (%), by Country
  • Figure 38. Asia Pacific Adenovirus Vector Vaccine Share (%), by Country
  • Figure 39. Europe Adenovirus Vector Vaccine Share (%), by Country
  • Figure 40. MEA Adenovirus Vector Vaccine Share (%), by Country
  • Figure 41. North America Adenovirus Vector Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Creative Biolabs (United States)
  • Sartorius AG (Germany)
  • Lonza (Switzerland)
  • Merck KGaA (Germany)
  • Cobra Biologics (United States)
  • Thermo Fisher Scientific (United States)
  • Boehringer Ingelheim (Germany)
  • Oxford Biomedica (United Kingdom)
  • Advanced Bioscience Laboratories (United States)
Select User Access Type

Key Highlights of Report


May 2023 232 Pages 61 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Adenovirus Vector Vaccine Market Quantitative research analysis
Global Adenovirus Vector Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Creative Biolabs (United States), Sartorius AG (Germany), Lonza (Switzerland), Merck KGaA (Germany), Cobra Biologics (United States), Thermo Fisher Scientific (United States), Boehringer Ingelheim (Germany), Oxford Biomedica (United Kingdom) and Advanced Bioscience Laboratories (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing investment in vaccine and drug development " is seen as one of major influencing trends for Adenovirus Vector Vaccine Market during projected period 2022-2028.
The Adenovirus Vector Vaccine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Adenovirus Vector Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Goserelin Drug Comprehensive Study by Indication (Prostate Cancer, Breast Cancer, Endometriosis, Gynaecological Disorders), Sales Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), Dose (...
$ 3500
Paediatric Palliative Care Drugs Comprehensive Study by Type (Paracetamol, Ibuprofen, Morphine, Others), Route of Administration (Oral, Topical, Parenteral), Distribution Channel (Hospital Pharmacies...
$ 3450
Drug Repurposing Comprehensive Study by Type (De novo drug discovery, Personalized Medicine, Genomics, Gene Editing), Application (Discovering drug targets,, Identifying and optimizing lead compounds...
$ 3650
Cyclobenzaprine Comprehensive Study by Patient Type (Adult, Pediatric), Form (Tablet, Capsule), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies), Dosage (5 mg, 7.5 mg,...
$ 3350
Pharmaceutical Contract Development and Manufacturing Comprehensive Study by Application (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users), Services (Pharmaceut...
$ 3750
Tablet Coatings Comprehensive Study by Type (Sugar Coating, Sealing, Sub Coating, Syrup Coating, Colouring, Polishing), Application (Nutraceuticals, Pharmaceuticals), Polymers (Cellulosic, Vinyl, Acr...
$ 3500